BACKGROUND: The tumor microenvironment (TME) is critical to every aspect of cancer biology. Organotypic tumor slice cultures (TSCs) preserve the original TME and have demonstrated utility in predicting drug sensitivity, but the association between clinicopathologic parameters and in vitro TSC behavior has not been well-defined. METHODS: One hundred and eight fresh tumor specimens from liver resections at a tertiary academic center were procured and precisely cut with a Vibratome to create 250 μm × 6 mm slices. These fixed-dimension TSCs were grown on polytetrafluoroethylene inserts, and their metabolic activities were determined by a colorimetric assay. Correlation between baseline activities and clinicopathologic parameters was assessed. Tissue CEA mRNA expression was determined by RNAseq. RESULTS: By standardizing the dimensions of a slice, we found that adjacent tumor slices have equivalent metabolic activities, while those derived from different tumors exhibit >30-fold range in baseline MTS absorbances, which correlated significantly with the percentage of tumor necrosis based on histologic assessment. Extending this to individual cancers, we were able to detect intra-tumoral heterogeneity over a span of a few millimeters, which reflects differences in tumor cell density and Ki-67 positivity. For colorectal cancers, tissue CEA expression based on RNAseq of tumor slices was found to correlate with clinical response to chemotherapies. CONCLUSIONS: We report a standardized method to assess and compare human cancer growth ex vivo across a wide spectrum of tumor samples. TSC reflects the state of tumor behavior and heterogeneity, thus providing a simple approach to study of human cancers with an intact TME. 2020 Annals of Translational Medicine. All rights reserved.
BACKGROUND: The tumor microenvironment (TME) is critical to every aspect of cancer biology. Organotypic tumor slice cultures (TSCs) preserve the original TME and have demonstrated utility in predicting drug sensitivity, but the association between clinicopathologic parameters and in vitro TSC behavior has not been well-defined. METHODS: One hundred and eight fresh tumor specimens from liver resections at a tertiary academic center were procured and precisely cut with a Vibratome to create 250 μm × 6 mm slices. These fixed-dimension TSCs were grown on polytetrafluoroethylene inserts, and their metabolic activities were determined by a colorimetric assay. Correlation between baseline activities and clinicopathologic parameters was assessed. Tissue CEA mRNA expression was determined by RNAseq. RESULTS: By standardizing the dimensions of a slice, we found that adjacent tumor slices have equivalent metabolic activities, while those derived from different tumors exhibit >30-fold range in baseline MTS absorbances, which correlated significantly with the percentage of tumor necrosis based on histologic assessment. Extending this to individual cancers, we were able to detect intra-tumoral heterogeneity over a span of a few millimeters, which reflects differences in tumor cell density and Ki-67 positivity. For colorectal cancers, tissue CEA expression based on RNAseq of tumor slices was found to correlate with clinical response to chemotherapies. CONCLUSIONS: We report a standardized method to assess and compare human cancer growth ex vivo across a wide spectrum of tumor samples. TSC reflects the state of tumor behavior and heterogeneity, thus providing a simple approach to study of human cancers with an intact TME. 2020 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Organotypic; cancer model; heterogeneity; microenvironment
Authors: David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga Journal: N Engl J Med Date: 2015-08-20 Impact factor: 91.245
Authors: Xiuyun Jiang; Y David Seo; Jae Hyuck Chang; Andrew Coveler; Eslam N Nigjeh; Sheng Pan; Florencia Jalikis; Raymond S Yeung; Ian N Crispe; Venu G Pillarisetty Journal: Oncoimmunology Date: 2017-05-25 Impact factor: 8.110
Authors: A D Rodriguez; L F Horowitz; K Castro; H Kenerson; N Bhattacharjee; G Gandhe; A Raman; R J Monnat; R Yeung; R C Rostomily; A Folch Journal: Lab Chip Date: 2020-04-09 Impact factor: 6.799
Authors: Giacomo Domenici; Gonçalo Trindade; Marta F Estrada; Ana Luísa Cartaxo; Paula M Alves; Saudade André; Catarina Brito Journal: Methods Mol Biol Date: 2022
Authors: Neda Jabbari; Heidi L Kenerson; Christopher Lausted; Xiaowei Yan; Changting Meng; Kevin M Sullivan; Priyanka Baloni; Dani Bergey; Venu G Pillarisetty; Leroy E Hood; Raymond S Yeung; Qiang Tian Journal: Cell Rep Med Date: 2020-12-22
Authors: Abby R Templeton; Penny L Jeffery; Patrick B Thomas; Mahasha P J Perera; Gary Ng; Alivia R Calabrese; Clarissa Nicholls; Nathan J Mackenzie; Jack Wood; Laura J Bray; Ian Vela; Erik W Thompson; Elizabeth D Williams Journal: Front Oncol Date: 2021-12-20 Impact factor: 6.244